ProfileGDS5678 / 1437799_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 29% 30% 29% 29% 30% 30% 29% 29% 38% 30% 30% 29% 29% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6988929
GSM967853U87-EV human glioblastoma xenograft - Control 22.6829330
GSM967854U87-EV human glioblastoma xenograft - Control 32.6696829
GSM967855U87-EV human glioblastoma xenograft - Control 42.6117129
GSM967856U87-EV human glioblastoma xenograft - Control 52.6324930
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7651530
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7173229
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6521129
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8402138
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6642730
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6673130
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6387329
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6677329
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6740830